Maze Therapeutics grants director 36K options at $27.665

Maze Therapeutics director Sophie Kornowski received a grant of 36,000 stock options on August 13, 2026.

Rhea-AI Filing Summary

Maze Therapeutics director Sophie Kornowski received a grant of 36,000 stock options on August 13, 2026. The options have an exercise price of $27.665 per share and expire on August 12, 2036. They vest in 36 equal monthly installments beginning September 13, 2026, contingent on her continued service.

Insider Trade Summary

Grant/Award: 36,000 shares

Grant/Award 1 txn

Insider Kornowski Sophie

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	36,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 36,000 contracts (Direct)

Footnotes (1)

1. F1. The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Key Figures

Options Granted: 36,000 shares Exercise Price: $27.665 per share Underlying Shares: 36,000 shares +3 more

6 metrics

Options Granted 36,000 shares Stock Option (Right to Buy) grant on August 13, 2026

Exercise Price $27.665 per share Conversion or exercise price of the granted stock options

Underlying Shares 36,000 shares Common Stock underlying the stock option grant

Expiration Date August 12, 2036 Expiration of the stock option grant

Vesting Start Date September 13, 2026 First 1/36th tranche of the options vests on this date

Post-Transaction Holdings 36,000 derivative securities Total stock options held following this grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, underlying security

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 27.6650"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option shall vest as to 1/36th of the total award monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying security financial

"underlying_security_title: Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MAZE director Sophie Kornowski receive in this Form 4 filing?

She received a grant of 36,000 stock options to purchase Maze Therapeutics common stock. The options represent equity-based compensation and give her the right to buy shares at a fixed exercise price over time.

What is the exercise price of the Maze Therapeutics (MAZE) stock options granted?

The options have an exercise price of $27.665 per share. This is the price at which Sophie Kornowski can purchase Maze Therapeutics common stock when the options vest and are exercised, if she chooses to do so.

When do the newly granted MAZE stock options begin vesting?

The options begin vesting on September 13, 2026. At that time, the first monthly tranche vests, and additional equal tranches vest on each monthly anniversary, subject to her continued service with Maze Therapeutics.

How do the 36,000 Maze Therapeutics (MAZE) options vest over time?

The grant vests as to 1/36th of the total award each month. This means 36 equal monthly installments, starting September 13, 2026, provided Sophie Kornowski continues serving Maze Therapeutics on each vesting date.

When do the Maze Therapeutics (MAZE) stock options granted to Sophie Kornowski expire?

These options expire on August 12, 2036. After this expiration date, any unexercised portion of the 36,000 stock options can no longer be exercised to purchase Maze Therapeutics common stock.

How many Maze Therapeutics (MAZE) derivative securities does Sophie Kornowski hold after this grant?

Following the transaction, she holds 36,000 stock options as reported. These options are derivative securities that represent the right to acquire an equivalent number of Maze Therapeutics common shares upon exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/17/2026 - 04:52 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kornowski Sophie

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.665	08/13/2026		A		36,000		(1)	08/12/2036	Common Stock	36,000	$0	36,000	D

Explanation of Responses:

1. The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)